Prostate Cancer Study Provides Evidence of Utility of Targeted Treatment in Metastatic Disease

Sep 30, 2019

|

BARCELONA – A new prostate cancer study has showed that biomarker-driven targeted treatments improve the survival of patients with metastatic disease.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Prostate Cancer Study Provides Evidence of Utility of Targeted Treatment in Metastatic Disease

To read the full story....

Breaking News

Myriad Genetics Seeks Supplemental Approval of HRD Test as CDx for GSK Ovarian Cancer Drug

UK's NICE Will Not Recommend Osimertinib for Untreated Non-Small Cell Lung Cancer

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

T Cell Assessment in Primary Melanomas Can Help Predict Metastatic Recurrence

Genetic Testing Challenges in Oncology: Patient Told Genetic Test was Negative Turns out to be MAP Carrier

FDA Accepts Bridge Biotherapeutics' Investigational New Drug Application for Lung Cancer Drug

Featured White Papers

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Long-Read Sequencing of Human Transcription Provides Insights into Metastatic Cancer

What's Popular?

Myriad Genetics Seeks Supplemental Approval of HRD Test as CDx for GSK Ovarian Cancer Drug

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

B Cell Gene Expression Profiling May Enable Cancer Immunotherapy CDx Test

Viral Cancer Early Detection Efforts Making Progress Toward the Clinic

Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

Sponsorships